Information Provided By:
Fly News Breaks for October 16, 2015
EW
Oct 16, 2015 | 07:53 EDT
Canaccord said Edwards Lifesciences' Sapien 3 results could expand the market opportunity if its TAVI data proves safe and efficacious in lower risk patients. The approval of Sapien 3 could drive upside to operating margins and earnings. Canaccord reiterated its Buy rating and $178 price target on Edwards Lifesciences shares.